Dermatology Reports (Mar 2022)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino,
Niccolò Siliquini,
Gianluca Avallone,
Michela Ortoncelli,
Pietro Quaglino,
Paolo Dapavo,
Simone Ribero

Affiliations

Luca Mastorino: University of Turin, Department of Medical Sciences
Niccolò Siliquini: University of Turin, Department of Medical Sciences
Gianluca Avallone: University of Turin, Department of Medical Sciences
Michela Ortoncelli: University of Turin, Department of Medical Sciences
Pietro Quaglino: University of Turin, Department of Medical Sciences
Paolo Dapavo: University of Turin, Department of Medical Sciences
Simone Ribero: University of Turin, Department of Medical Sciences

DOI: https://doi.org/10.4081/dr.2022.9282

Abstract

not available

psoriasis, Guselkumab, cancer, IL-23, neoplasia, biological therapy

Published in Dermatology Reports

ISSN: 2036-7392 (Print); 2036-7406 (Online)
Publisher: PAGEPress Publications
Country of publisher: Italy
LCC subjects: Medicine: Dermatology
Website: https://www.pagepress.org/journals/index.php/dr

About the journal